When applied in vivo in mouse models of lung and colon cancer, it enhanced CD4+ and CD8+ T-cell expansion and attenuated both PD-1 expression and Treg accumulation, highlighting its potential synergy with ICB therapy [314]. The gene discussed is PDCD1; the disease is colonic neoplasm.